Pro-Dex (PDEX) Competitors

Pro-Dex (NASDAQ:PDEX) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability.

Is PDEX or AXGN more profitable?

Pro-Dex has a net margin of 9.17% compared to AxoGen's net margin of -7.91%. Pro-Dex's return on equity of 16.74% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	9.17%	16.74%	9.98%
AxoGen	-7.91%	-14.91%	-7.49%

Do institutionals and insiders hold more shares of PDEX or AXGN?

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 47.5% of Pro-Dex shares are owned by company insiders. Comparatively, 7.0% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media refer more to PDEX or AXGN?

In the previous week, AxoGen had 1 more articles in the media than Pro-Dex. MarketBeat recorded 2 mentions for AxoGen and 1 mentions for Pro-Dex. AxoGen's average media sentiment score of 1.44 beat Pro-Dex's score of 0.30 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in PDEX or AXGN?

AxoGen received 299 more outperform votes than Pro-Dex when rated by MarketBeat users. Likewise, 72.71% of users gave AxoGen an outperform vote while only 61.85% of users gave Pro-Dex an outperform vote.

Company	Underperform	Outperform
Pro-Dex	Outperform Votes 154 61.85%	Underperform Votes 95 38.15%
AxoGen	Outperform Votes 453 72.71%	Underperform Votes 170 27.29%

Do analysts rate PDEX or AXGN?

Pro-Dex currently has a consensus target price of $52.00, suggesting a potential upside of 6.69%. AxoGen has a consensus target price of $15.00, suggesting a potential downside of 4.09%. Given Pro-Dex's higher possible upside, research analysts plainly believe Pro-Dex is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
AxoGen	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better earnings and valuation, PDEX or AXGN?

Pro-Dex has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$56.80M	2.80	$2.13M	$1.54	31.65
AxoGen	$180.86M	3.81	-$21.72M	-$0.32	-48.88

Which has more volatility and risk, PDEX or AXGN?

Pro-Dex has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Summary

AxoGen beats Pro-Dex on 9 of the 17 factors compared between the two stocks.